Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1 19Phase 1/2 17Phase 3 3Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Head & Neck 4Gastrointestinal 3Dermatologic 3Gynecologic 2Genitourinary 2Tumor-Agnostic 1CNS 1

Conditions

Glioma 1

Interventions

Magnetic Resonance Spectroscopy 52Radiosurgery 38Radiotherapy 24Blood Specimen Collection 21Magnetic Resonance Imaging 17Bevacizumab 16Temozolomide 13Radiation 12Proton Therapy 10Specimen Handling 9Radiotherapy, Intensity-Modulated 9Mental Status and Dementia Tests 9Carboplatin 9Surgical Procedures, Operative 8Exercise 8Dexmedetomidine 8Vincristine 7Surveys and Questionnaires 7Spinal Puncture 7Etoposide 7Drug Therapy 7Biopsy 7Saline Solution 6Diffusion Tensor Imaging 6Dexamethasone 6Cyclophosphamide 6Therapeutics 5Standard of Care 5Restraint, Physical 5Propofol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × pembrolizumab × CNS × Clear all
NCT02658279 2026-03-03

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Memorial Sloan Kettering Cancer Center

Phase NA Active not recruiting
27 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡